Short-Duration Treatment Regimens for Chronic HCV Infection

Eight weeks of a triple direct-acting antiviral regimen was highly effective in HCV genotype 1 and even in genotype 3 in the absence of cirrhosis.

Twelve weeks — or, in certain situations, 8 weeks — is the current standard duration of direct-acting antiviral (DAA) regimens for the treatment of chronic hepatitis C virus (HCV) infection. Shorter regimens are desirable to reduce cost and improve compliance.

In an industry-funded, single-center trial, investigators assessed the efficacy of elbasvir 100 mg (NS5A inhibitor)/grazoprevir 50 mg (NS3/4A inhibitor) and sofosbuvir 400 mg (NS5B inhibitor) for durations of 4–12 weeks in 143 treatment-naive patients with HCV genotype 1 or 3 infection. Genotype 1 treatment failures were retreated with the same regimen plus ribavirin for 12 weeks. The primary endpoint was assessment of HCV RNA <15 IU/mL at 12 weeks after treatment was completed (SVR12)…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Short-Duration Treatment Regimens for Chronic HCV Infection

Topics

Reviewing Author